Luglio 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics e GenScript ProBio stanno firmando un contratto per lo sviluppo e la produzione di vettori di plasmidi e virus per la prima pipeline della Advanced CAR-T Platform (piattaforma ACT) di ACT Therapeutics, che sarà anche incaricata di produrre materie prime per i successivi gasdotti di ACT Therapeutics. Il contratto riguarderà la produzione di plasmidi e vettori di virus per la prima pipeline della piattaforma CAR-T avanzata di ACT Therapeutics.
Come risultato di questo accordo, GenScript ProBio è stato elevato allo status di partner globale in grado di supportare le piattaforme ACT per le terapie ACT.
La piattaforma ACT è una tecnologia di terapia genica e cellulare di nuova generazione che prende di mira gli antigeni del cancro inserendo geni progettati per indirizzare quegli antigeni nelle cellule immunitarie. Questi geni vengono consegnati nelle cellule immunitarie attraverso l'uso di vettori virali. GenScript ProBio possiede uno sviluppo di processi vettoriali di virus di alta qualità e una piattaforma di servizi unica per la produzione di GMP, entrambi necessari per lo sviluppo della terapia cellulare e genica.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing cancro al sangue. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, CEO di ACT Therapeutics, ha dichiarato: “Abbiamo completato i preparativi per l'emergere della piattaforma ACT a livello globale attraverso una partnership strategica con GenScript ProBio. Accelereremo lo sviluppo di trattamenti mirati ai tumori solidi refrattari e intrattabili”.
Informazioni su GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Verso la missione di "Innovazione attraverso la collaborazione", GenScript ProBio si impegna ad aiutare i clienti ad abbreviare i tempi per lo sviluppo di farmaci biologici dalla scoperta alla commercializzazione, riducendo significativamente i costi di ricerca e sviluppo e costruendo un futuro più sano.
